v3.26.1
Consolidated balance sheets - USD ($)
$ in Millions
Jun. 30, 2026
Dec. 31, 2025
Non-current assets [abstract]    
Property, plant and equipment $ 10,685 $ 10,782
Right-of-use assets 1,582 1,570
Goodwill 26,767 25,567
Intangible assets other than goodwill 42,074 29,411
Investments in associated companies 69 98
Deferred tax assets 5,277 5,438
Financial assets 2,302 2,348
Other non-current assets 5,926 5,275
Total non-current assets 94,682 80,489
Current assets [abstract]    
Inventories 6,220 6,269
Trade receivables 9,636 8,937
Income tax receivables 218 205
Marketable securities, time deposits and derivative financial instruments 74 155
Cash and cash equivalents 7,616 11,435
Other current assets 3,587 3,459
Total current assets 27,351 30,460
Total assets 122,033 110,949
Equity [abstract]    
Share capital 736 766
Treasury shares (49) (50)
Reserves 40,855 45,414
Equity attributable to Novartis AG shareholders 41,542 46,130
Non-controlling interests 404 419
Total equity 41,946 46,549
Non-current liabilities [abstract]    
Financial debts 37,489 27,935
Lease liabilities 1,663 1,657
Deferred tax liabilities 5,292 3,397
Provisions and other non-current liabilities 3,895 4,133
Total non-current liabilities 48,339 37,122
Current liabilities [abstract]    
Trade payables 4,258 4,456
Financial debts and derivative financial instruments 9,588 5,602
Lease liabilities 274 263
Current income tax liabilities 2,312 1,969
Provisions and other current liabilities 15,316 14,988
Total current liabilities 31,748 27,278
Total liabilities 80,087 64,400
Total equity and liabilities $ 122,033 $ 110,949